COPD and housing

Chronic Obstructive Pulmonary Disease is, on paper, an irreversible disease driven principally by smoking history. In practice, the day-to-day burden — exacerbation frequency, hospital admissions, and the slow loss of independence — is heavily moderated by the patient's housing environment. Cold homes drive bronchoconstriction. Damp drives infection risk. Indoor combustion (gas hobs, open fires, paraffin heaters) drives PM2.5 and NO2 spikes that aggravate already-narrowed airways.

This page is for the GP, respiratory nurse, or community matron deciding whether the next intervention is a stronger inhaler, an oxygen prescription, or a referral that ends with the heating system being replaced.

Exacerbation triggers — cold, damp, indoor air

The classical trigger list for COPD exacerbation is viral infection, bacterial colonisation, and air pollution. The housing-mediated version of that list is more granular:

• Cold: Inhaling air below approximately 10°C provokes bronchoconstriction in patients with airway hyperresponsiveness. Living in a home that drops to 13-15°C overnight and 16°C during the day means the patient is inhaling cold air for hours at a time.
• Damp and mould: Persistent damp creates a microbial reservoir. Even where overt fungal infection does not occur, the immune burden contributes to exacerbation frequency.
• Indoor combustion: A gas hob in a small kitchen with no extract ventilation can push NO2 above WHO guideline values within minutes. Open fires and unflued gas heaters are still common in older UK housing stock.
• Secondhand smoke: Often overlooked. A non-smoking COPD patient living with a smoker has measurable PM2.5 exposure indoors.

GOLD severity staging and housing implications

The GOLD framework stages COPD by airflow obstruction (FEV1) and by symptom and exacerbation burden (groups A-D, now A-E in the updated framework). Housing intervention is relevant at every stage, but the ROI shifts as severity progresses.

The clinical observation that drives this: a patient who is admitted twice a winter is paying — through the NHS, but ultimately through the system — far more than the cost of fixing their home. The economics of preventive retrofit at GOLD E are extremely favourable.

Oxygen therapy and heating cost

Long-term oxygen therapy (LTOT) requires the patient to use the device 15+ hours per day to gain the survival benefit. For a frail patient on a fixed income, the friction is real: the concentrator runs on electricity, the home is often under-heated to save on bills, and the patient ends up rationing both heat and oxygen.

The financial reality:

A heat pump with proper insulation typically reduces total annual energy cost for a small home from the £2,000-2,500 range to £400-600. For a household where the patient is using LTOT, that delta is the difference between heating the home properly and rationing.

When retrofit is a clinical intervention

Retrofit becomes a clinical intervention — meaning it should be considered alongside pharmacology rather than as a wellbeing extra — when:

• Two or more exacerbations in 12 months requiring oral corticosteroids or antibiotics
• One or more hospital admissions for exacerbation in 12 months
• Patient on LTOT or being assessed for LTOT
• Home temperature documented below 18°C in heating season (community matron or OT visit)
• Visible damp or mould reported by patient or family
• Indoor combustion present (gas hob without extract, open fire, paraffin heater) and patient lacks resources to upgrade

The intervention package, in priority order:

1. Damp remediation if present (immediate)
2. Ventilation strategy (MVHR or continuous mechanical extract)
3. Insulation (loft, walls, floor as appropriate)
4. Heating upgrade (heat pump preferred where envelope supports it; modern condensing gas otherwise)
5. Removal of indoor combustion sources where feasible

Smoking and indoor combustion

For COPD specifically, the smoking conversation cannot be skipped, but it does not exhaust the indoor air conversation. A patient who has stopped smoking ten years ago still has fixed airflow obstruction, and they still benefit from clean indoor air. A patient who has not stopped smoking still benefits from heating, ventilation, and damp remediation — the housing intervention is not contingent on cessation.

What is worth flagging clearly: improving indoor air with MVHR while continuing to smoke indoors will not deliver the full benefit, because the smoking is a far larger PM source than ventilation can clear in real time. The honest framing is that retrofit and cessation are complementary, and either alone helps.

Indoor combustion sources beyond smoking deserve specific attention in older UK housing stock. Open fires release particulate matter, NO2, and CO at levels that can dominate the indoor air profile during the heating season. Paraffin heaters and unflued bottled gas heaters — still in use in some rural and off-grid properties — are particularly problematic for COPD patients because they release combustion products directly into the breathing zone. Replacing these with electric heating or, where suitable, a heat pump is one of the highest-leverage single interventions for an at-risk patient.

When to refer — COPD-specific criteria

Concrete referral criteria for COPD patients to the retrofit pathway:

• GOLD group B, C, D, or E with self-reported cold home, draughts, or visible damp
• Two or more exacerbations requiring oral corticosteroids in 12 months
• One or more hospital admissions for exacerbation in 12 months
• Patient on long-term oxygen therapy or being assessed for LTOT
• Use of indoor combustion (open fire, paraffin heater, unflued gas heater) as primary heat source
• Living in property pre-1990 with no recent insulation or heating upgrade
• Co-resident smoker affecting non-smoking COPD patient
• Patient on income-related benefits (qualifies for ECO4 standard route)

Two or more of the above warrant a referral. The threshold is deliberately low because the COPD patient is highly leveraged — a single avoided exacerbation represents real clinical and economic value, and the housing intervention pays back across multiple winters.

Pulmonary rehabilitation and the home environment

Pulmonary rehabilitation is a structured 6-8 week programme of supervised exercise and education for people with chronic respiratory conditions, primarily COPD. The clinical evidence base is strong — pulmonary rehab improves exercise tolerance, reduces breathlessness, and reduces hospital admissions. The programme is typically delivered in a community or hospital outpatient setting, but the home environment between sessions and after the programme finishes is where the gains are either consolidated or lost.

A patient who completes pulmonary rehab and returns each evening to a 14°C home with damp bedrooms loses much of the benefit within months. Conversely, a patient with a warm, well-ventilated home maintains and builds on the rehab gains. This is one of the cleanest places to intervene because the patient is already engaged with respiratory care, motivated, and identifiable.

The pulmonary rehab team can incorporate a single housing assessment question into intake and discharge — does the patient feel their home supports their breathing? A 'no' or 'sometimes' triggers the retrofit referral pathway. This is a low-cost, low-friction addition to existing practice.

COPD is a long-game disease, and the home is where the long game is played out. A patient whose home is warm, dry, and well-ventilated will exacerbate less often, recover faster from each event, and retain independence longer. None of that is replaceable by another inhaler.